Skip to content

Clinical trial of chronically implanted retinal prosthesis by Suprachoroidal-Transretinal Stimulaiton in patient with retinitis pigmentosa

Clinical trial of chronically implanted retinal prosthesis by Suprachoroidal-Transretinal Stimulaiton in patient with retinitis pigmentosa - Clinical trial of chronically implanted retinal prosthesis by Suprachoroidal-Transretinal Stimulaiton

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000012754
Enrollment
3
Registered
2014-01-04
Start date
2013-09-12
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

retinitis pigmentosa

Interventions

Implantation of retinal prosthesis

Sponsors

Department of Applied Visual Science, Osaka University Graduate School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Patients who are diagnosed retinitis pigmentosa by multiple ophthalmologists. 2. Patients whose visual acuity are hand motion, light perception, or no light perception. 3. Patients who do not have any severe disease except from eye diseases. 4. Patients who are able to live independent daily life and walk using a white cane. 5. Patients who can go to the hospital for regular examinations after the surgery. 6. Patient's family members are able to take care of their daily living. 7. The age limits are from 40 to 75 years old. 8. Written informed consent is obtained from the patient.

Exclusion criteria

Exclusion criteria: 1. Patients with glaucoma, optic nerve disease, or retinal disease except from retinitis pigmentosa. 2. Patients with intracranial disease such as cerebral infarction or brain tumor. 3. Patients who are implanted any electrical device such as a cochlear implant or a deep brain stimulation. 4. Patients who are pregnant. 5. Patients with epilepsy. 6. Patients who cannot find phosphenes by electrical stimulation through cornea with less than 1.5 mA 7. Patients who refuse to receive treatment. 8. Patients who are decided by physicians in charge as being inappropriate this clinical trial.

Design outcomes

Primary

MeasureTime frame
Efficacy; comparison of the results of localization test, motion test, grating acuity, and mobility test. Safety; slit lamp examination, funduscopy and device check

Secondary

MeasureTime frame
Efficacy; mobility test, questionnaire for quality of vision, PET, and NIRS Safety; fluorescein angiography, eye-movement test, OCT,and phosphene test in transcorneal-stimulation

Countries

Japan

Contacts

Public ContactTakashi Fujikado

Osaka University Graduate School of Medicine Department of Applied Visual Science

fujikado@ophthal.med.osaka-u.ac.jp06-6879-3941

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026